Drug therapy of unstable bladder. Clinical trial with tolterodine in 16.000 patients;Medikamentose therapie der instabilen blase. Anwendungsbeobachtung mit tolterodin bei 16.000 patienten

Urologe - Ausgabe B

Volumn 40, Issue 2, 2000, Pages 161-165

  Hofner K ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TOLTERODINE;

ARTICLE; BLADDER INSTABILITY; CLINICAL TRIAL; HUMAN; MAJOR CLINICAL STUDY;

EID: 0034027980     PISSN: 00421111     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001310050356     Document Type: Article

References (13)

1. Appell RA (1997) Clinical efficacy and safety of tolterodine in the treatment of overactive bladder a pooled analysis. Urology 50 [Suppl 6A]: 90-96
2. Drutz HP, Appell RA, Gleason D et al. (1998) Long term treatment with tolterodine in patients with overactive bladder. 28th Annual Meeting of the International Continence Society, Sept 14-17, Jerusalem, Israel
3. Johannesson M, O'Conor RM, Kobelt-Nguyen G et al. (1997) Willingness to pay for reduced incontinence problems. Br J Urol 80: 557-562
4. Kobelt-Nguyen G, Johannesson M, Mattiasson A et al. (1997) Correlations between symptoms of urge incontinence and scores of a generic quality of life instrument (SF36) and health status measurements (Euro-Qol) and between changes in symptoms and Qol scores. 27th Annual Meeting of the International Continence Society, Sept 23-26, Yokohama, Japan
5. Komaroff AL, Fagioli LR, Doolittle TH et al. (1996) Health status in patients with chronic fatigue syndrome and in general population and disease comparison groups. Am J Med 101: 281-290
6. Larsson G, Hallén B, Nilvebrant L (1996) Tolterodine in the treatment of urge incontinence. Analysis of the pooled phase II efficacy and safety data. 26th Annual Meeting of the International Continence Society, Aug 27-30, Athens, Greece
7. Malone-Lee JG, Wagg A, Larsson G (1998) Age comparisons of the safety and efficacy of tolterodine from twelve week studies. 28th Annual Meeting of the International Continence Society, Sept 14-17, Jerusalem, Israel
8. Nilvebrant L, Andersson K-E, Gillberg P-G et al. (1997) Tolterodine - a new bladder selective antimuscarinic agent. Eur J Pharmacol 327: 195-207
9. Nilvebrant L, Gillberg P-G, Sparf B (1997) Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine. Pharmacol Toxicol 81: 169-172
10. Nilvebrant L, Hallén B, Larsson G (1997) Tolterodine - a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci 60: 1129-1136
11. Schellenberg R (1998) Objektive Erfassung von zentralen Nebenwirkungen peripher wirksamer Pharmaka anhand des EEG. Gesellschaft für Inkontinenzhitfe e. V., Referateband 1998, 10 Deutscher Kongreß der GIH, Kassel
12. Sifo Research & Consulting AB (1998) SIFO-Studie. i. A. von Pharmacia & Upjohn, data on file
13. Stahl MMS, Ekström B, Sparf B et al. (1995) Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity. Neurorol Urodyn 14 647-655